2025 Meningococcal Vaccines Market Outlook: Key Indicators Shaping Growth Through 2034

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Meningococcal Vaccines Market Through 2025?
The market for meningococcal vaccines has experienced swift expansion in the past few years. Expected to rise from $3.89 billion in 2024 to $4.29 billion in 2025, it has a projected compound annual growth rate (CAGR) of 10.3%. This remarkable growth during the historic period can be linked to factors such as the prevalence of the disease, trends in worldwide travel, the state of healthcare infrastructure, readiness for epidemics, and the extent of health insurance coverage.

What's the Projected Size of the Global Meningococcal Vaccines Market by 2029?
In the coming years, the meningococcal vaccines market is anticipated to experience robust expansion. By 2029, it is projected to reach a valuation of $6.18 billion at a compound annual growth rate (CAGR) of 9.5%. The growth anticipated during the forecast period is a result of factors such as the appearance of new strains, augmented globalization, rising healthcare investment, health initiatives and transformations in the regulatory framework. Key trends expected during the forecast period encompass personalized vaccines, digital immunization records, gene editing technologies, multi-valent vaccines, and subscription-based vaccine models.

View the full report here:
https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Top Growth Drivers in the Meningococcal Vaccines Industry: What's Accelerating the Market?
The advancement of the meningococcal vaccine market is projected to be driven by a surge in healthcare expenditures. The term healthcare encompasses various establishments such as residential care facilities, nursing homes, and intermediate care facilities for individuals suffering from mental disorders or mental retardation. The elevated cost of new vaccine generations as compared to their earlier counterparts has emerged as a central point in debates regarding the justification of their prices in light of their benefits. The thorough examination of the full societal and financial benefits of vaccination is becoming a progressively crucial topic of research in the vaccine valuation literature. For example, an article posted by the American Medical Association, a group representing US physicians and medical students, in May 2022 indicated that healthcare expenditures in the US had escalated by 9.7% to $4.1 trillion, or $12,530 per individual. This growth rate noticeably exceeds that of 2019 (4.3%). Consequently, a rise in healthcare expenditure is fueling the expansion of the meningococcal vaccine market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

What Trends Will Shape the Meningococcal Vaccines Market Through 2029 and Beyond?
Leading firms in the meningococcal vaccines market are innovating new vaccines to prevent various serogroups, enhancing their market profitability. Meningococcal vaccines serve as preventive tactics against infections caused by certain serogroups of Neisseria meningitidis bacteria. For instance, in October 2023, the US pharmaceutical giant, Pfizer Inc., obtained FDA approval for its vaccine, PENBRAYA. Providing wide serogroup protection, PENBRAYA is the most all-encompassing meningococcal vaccine approved in the U.S, defending against A, B, C, W, and Y groups. FDA endorsed the vaccine based on persuasive Phase 2 and 3 trial data, verifying its similar immunogenicity to Trumenba + Menveo across all serogroups, allied with an encouraging safety profile. In September 2022, Pfizer announced affirmative results from a Phase 3 trial that compared PENBRAYA to other licensed meningococcal vaccines, focusing on safety, tolerability, and immunogenicity.

What Are the Main Segments in the Meningococcal Vaccines Market?
The meningococcal vaccines market covered in this report is segmented -

1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine
2) By Serotype: Men Acwy, Men B/Bc, Men C
3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults
4) By Distribution Channel:: Pharmacies, Community Clinics, Public Health Agencies, Other Channels
5) By End user: Hospitals, Research, Academic Institutes

Subsegments:
1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine
2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine
3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=8013&type=smp

Which Top Companies are Driving Growth in the Meningococcal Vaccines Market?
Major companies operating in the meningococcal vaccines market include Pfizer Inc., GlaxoSmithKline plc, Sanofi Pasteur, Merck & Co. Inc., Serum Institute of India Pvt. Ltd., Bio-Manguinhos, Walvax Biotechnology Co. Ltd., Bavarian Nordic A/S, Hualan Biological Engineering Inc., China National Pharmaceutical Group (Sinopharm), Bharat Biotech, Incepta Pharmaceuticals Ltd., Biological E. Limited, Chongqing Zhifei Biological Products Co. Ltd., Biokangtai, Biomed Pvt Ltd., Biocine SCL, Panacea Biotec Ltd., Grifols S.A., CSL Limited, Minhai Biotechnology Co. Ltd., Chiron Behring Vaccines Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd.

Which Regions Will Dominate the Meningococcal Vaccines Market Through 2029?
North America was the largest region in the meningococcal vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8013

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.